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identifying new cases (7) and that 
such investigation must be conducted 
periodically. Our data also indicate 
that subclinical infections are highly 
prevalent among public school 
students in the Amazon region and 
that identifying students with positive 
anti–PGL-I test results can lead to 
discovery of new leprosy cases among 
students’ household contacts.
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Novel Prion Protein 
in BSE-affected 
Cattle, Switzerland
To the Editor: In a recent issue 
of Emerging Infectious Diseases, 
Seuberlich et al. (1) reported a 
novel prion protein in cattle with 
bovine spongiform encephalopathy 
(BSE). Two cows in Switzerland, 8 
and 15 years of age, tested positive 
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No. new cases 
Among persons 
previously tested
Among contacts of 
persons previously tested Total† 
Leprosy patients Positive 14 43 9 4 13 
Negative 11 42 1 1 2 
Students Positive 11 84 5 5 10 
Negative 8 53 1 4 5 
Total  44 222 16 14 30 
*Households were selected from among 35 leprosy patients encountered during the first visit (25 households, 14 with an anti–PGL-I–positive contact in 
the household and 11 without) and among students with results of anti–PGL-I serology (19 households, 11 with an anti–PGL-I–positive contact in the 
household and 8 without). PGL-I, phenolic glycolipid-I. 
†Fisher exact test comparing case-patients and non–case-patients among those positive or negative for anti-PGL-I IgM revealed a statistically significant 
difference (p = 0.0280). 
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in 2 approved screening tests, the 
PrioSTRIP test and the Prionics 
Check WESTERN (Prionics, Zurich, 
Switzerland). According to World 
Organisation for Animal Health 
guidelines, the 2 cattle are considered 
BSE positive. Histopathologic and 
immunohistochemical results were 
inconclusive because the tissues were 
severely autolyzed. Clinical signs 
were absent or the clinical history was 
not known.
After further analysis of brain 
tissues by using several monoclonal 
antibodies in a Western blot (WB), 
the authors concluded that they had 
identifi ed an N-terminal truncated 
protease-resistant prion protein 
(PrPres) fragment that differs from the 
PrPres fragments in 3 known types of 
BSE. No reference was made to the 
existence of N-truncated fragments, 
such as C1, of the normal prion protein 
PrPC, which have been reported for 
humans (2,3), mice (4), and cattle and 
other ruminants (5). The pattern in 
the WB of the novel prion protein (1) 
appears similar to that of the fragment 
C1 of the normal prion protein (2–5). 
The C1 fragment is more protease 
resistant than the intact PrPC fragment 
because the protein part is more 
protected by the polysaccharide 
residues. Could it be that in the case 
of the severely autolyzed tissues of the 
cows in Switzerland, the proteinase 
K might already have been weakened 
or inhibited and when combined 
with the higher protease resistance of 
the C1 fragment, the digestion was 
incomplete?
Ten years ago, I looked at 
nonspecifi c, unusual samples from 
fallen stock cattle in New Zealand. 
Samples from these cattle had 
been confi rmed as negative by 
paraffi n-embedded tissue blot 
(University of Göttingen, Göttingen, 
Germany), sodium phosphotungstic 
acid precipitation, followed by 
WB (European Union Reference 
Laboratory for Transmissible Spongi-
form Encephalopathies, Veterinary 
Laboratories Agency, New Haw, 
UK), Prionics WB (Prionics 
AG, Zurich, Switzerland), histo-
pathologic examination, and immuno-
histochemical testing (Veterinary 
Laboratories Agency). We became 
aware of such samples when the 
proteinase K digestion did not work 
properly (Figure). Unusual samples 1 
and 2 contained increased amounts of 
a truncated fragment of normal PrPC, 
which was digested completely after 
the proteinase K concentration was 
increased.
I am convinced that the novel 
PrPres described in the article by 
Seuberlich et al. (1) is indeed a 
truncated fragment of the normal 
bovine PrPC protein. Therefore, I 
would like to ask the editor to address 
the following issues with the authors: 
Why were no references to truncated 
fragments of PrPC made in their 
article? Why was no WB analysis 
performed in which the novel PrPres 
was shown next to normal, undigested 
PrPC for band-size comparison? Why 
were no WB analyses shown in which 
the proteinase K concentration was 
increased?
It is laudable that in vivo 
transmission studies using transgenic 
mouse models and cattle are under 
way, which will sort out these 
fi ndings conclusively. I expect that no 
disease development will be shown. 
Meanwhile, announcing new types of 
BSE is purely speculation.
Reinhold Kittelberger
Author affi liation: Biosecurity New Zealand, 
Upper Hutt, New Zealand
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Figure. Western blot analysis of proteinase K (PK) digested brain stem samples with 
increasing concentrations of PK (relative to concentration used in the Prionics Check 
WESTERN (Prionics, Zurich, Switzerland). C, kit control, normal bovine brain homogenate; 
BSE, bovine spongiform encephalopathy sample from cow from Switzerland; unusual 
samples 1 and 2 and normal sample are from New Zealand cattle and had been confi rmed 
as negative by several test methods (see text). Unusual samples 1 and 2 show a higher 
concentration of a truncated fragment of the normal prion protein, which was completely 
digested at increased PK concentrations. It is typical for this fragment that bands are 
identical in size to lower bands of the normal prion protein in the undigested samples of 
normal brain homogenates (black arrowheads). White arrowheads show major bands of 
PK-digested BSE prion protein.
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In Response: Dr Kittelberger 
comments on our recent report of 
2 cows in Switzerland that were 
classifi ed as positive for bovine 
spongiform encephalopathy (BSE), 
according to the established criteria 
(1,2). He raises concerns that the 
unusual prion protein signature in 
Western blot (WB) in these cows 
represents a physiologic prion protein 
(PrPC) fragment, ineffi ciently degraded 
by proteinase K (PK), termed C1. 
Certainly the effects of tissue autolysis 
on PK activity and the molecular prion 
protein signature are of particular 
concern and deserve full consideration 
in data interpretation. In our study, 
molecular mass comparisons between 
PrPC in non-PK–treated brain tissue 
of healthy cattle and the prion protein 
in samples from the 2 aberrant cows 
with BSE in WB were considerably 
hindered by overlapping C1- and 
full-length PrPC bands in the non-PK–
treated samples and did not allow for 
a robust conclusion (T. Seuberlich, 
unpub. data). It is noteworthy that the 
Prionics Check WESTERN (Prionics, 
Zurich, Switzerland) test has been 
extensively validated in terms of 
the diagnostic specifi city, also on 
severely autolytic specimens (3–5). 
In none of these studies was a similar 
prion protein signature observed. We 
therefore considered it unlikely that the 
fi ndings in the cases from Switzerland 
resulted from tissue autolysis.
Dr Kittelberger provides data 
from New Zealand cattle that revealed 
a similar prion protein signature in 
WB. He assumes that these animals 
had a negative BSE status and that the 
PK digestion in the WB did not work 
properly, which is supported by results 
from other diagnostic techniques. 
However, information about the 
degree of autolysis of these samples 
is missing, and, most notably, whether 
these fi ndings are correlated with prion 
infectivity is not known. Strikingly, in 
contrast to the results for the samples 
from Switzerland, the samples 
from New Zealand are reported to 
be negative in the Prionics Check 
WESTERN. It would be fascinating to 
perform a side-by-side analysis of the 
samples from Switzerland and from 
New Zealand to determine whether the 
banding characteristics in both groups 
are identical. Studies are under way in 
our laboratory to further investigate 
the effect of tissue autolysis on PK 
activity and PrPC degradation under 
experimental conditions. If our 
fi ndings turn out to be the result of 
inhibited PK activity in BSE-negative 
cattle samples, the current diagnostic 
criteria might require revision. As long 
as the results of these experiments and 
the ongoing transmission studies are 
not available, we can neither confi rm 
nor reject a novel type of BSE.
Torsten Seuberlich
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